Key result
Adverse or no LV remodeling post-MitraClip linked to ~10-fold higher mortality and HF hospitalization risk.
Why the study?
The role of LV volumes and EF in selecting patients for the MitraClip procedure remains a matter of debate.
Does the pattern of left ventricular remodeling after MitraClip implantation predict mortality and heart failure hospitalization in patients with severe mitral regurgitation?
Observational (n=45)
Does the pattern of left ventricular remodeling after MitraClip implantation predict mortality and heart failure hospitalization in patients with severe mitral regurgitation?
Effect estimate: HR 10.08 (95% CI 1.29-78.6)
Absolute Event Rate: 50% vs 4.3%
p-value: p=0.006
After MitraClip implantation, adverse or no left ventricular remodeling occurs in about half of patients and is strongly associated with increased mortality and heart failure hospitalization.
Adverse post-MitraClip remodeling may flag patients needing closer surveillance; leaves open whether remodeling is causal or modifiable.
OBJECTIVE: The role of left ventricular (LV) volumes and ejection fraction (EF) in the selection of patients for the MitraClip procedure remains matter of debate. The goal of this study is to assess the pattern of LV remodeling and its clinical implications after MitraClip procedures, and to evaluate the role of LV ejection fraction (EF) in patient selection. METHODS: Complete echocardiography was performed before, at discharge, 1,6, and 12-months in 45 patients treated with MitraClip for severe mitral regurgitation (MR) [age 78.2 ± 8.3 yrs, NYHA 3.74 ± 0.44, EF 36.5 ± 12.8%]. From baseline to 6-month, reverse and adverse LV-R were defined as a ≥15% decrease in LV end-systolic volume and a ≥10% increase in LV end-systolic volume, respectively. RESULTS: At 6-month, sustained reduction of MR ≤ 2 was observed in all patients, but two; reverse, adverse, and no LV-R occurred in 51% (N = 23), 18% (N = 8), and 31% (N = 14) of patients, respectively. Baseline LV end-diastolic volume was an independent predictor of reverse LV-R [P = 0.004], whereas EF was not. During follow-up (17.5 ± 9.3 months) period, 50% of adverse/no LV-R patients were free of the composite endpoint (mortality and hospitalization for heart failure) compared to 95.7% of reverse LV-R patients (P = 0.006). In Cox analysis, adverse LV-R and adverse/no LV-R were associated with composite endpoint with adjusted hazard ratios of 5.6 (95% CI 1.65-19.00) and 10.08 (95% CI 1.29-78.6), respectively. CONCLUSION: After MitraClip implantation, sustained adverse or no LV-R occurred in one-in-two patients and was associated with poor prognosis. Large LV volumes may help us to avoid the futility of the procedure.
No takes yet. Share an insight, caveat, or question.
Carrabba et al. (2021) conducted an observational in severe mitral regurgitation (n=45). MitraClip vs. Reverse left ventricular remodeling was evaluated on composite endpoint (mortality and hospitalization for heart failure) (HR 10.08, 95% CI 1.29-78.6, p=0.006). Adverse or no left ventricular remodeling after MitraClip was associated with increased mortality and heart failure hospitalization compared to reverse remodeling (HR 10.08; 95% CI 1.29-78.6; P=0.006).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: